GLP-1s and Cardiovascular Risk: What the Latest Evidence Reveals

About this episode

Dr. Bret Scher discusses the implications of GLP-1 receptor agonists on cardiovascular risk and the importance of sustainable lifestyle changes alongside medication.

GLP-1 receptor agonists like semaglutide are often described as “game changers” for weight loss and cardiovascular health, and in many ways, the data support that claim. Clinical trials suggest meaningful reductions in major cardiovascular events, offering hope for individuals struggling with metabolic disease. But there’s an important nuance that deserves more attention: what happens when these medications are stopped? In this conversation, Dr. Bret Scher explores emerging real-world data showing that the benefits of GLP-1s, particularly for cardiovascular risk, appear to depend on continued use. For many individuals, stopping the medication leads to a reversal of progress, raising important questions about long-term strategy, sustainability, and what true metabolic healing looks like. Are we managing symptoms, or addressing root causes? What role should medications play in long-term care? How can we use powerful tools like GLP-1s to support , rather than replace, sustainable metabolic change? For some individuals, long-term use may be appropriate and beneficial. But we need to broaden the conversation toward approaches that aim to improve underlying metabolic health, support…

People in this episode

Host: Dr. Bret Scher

Topics covered

• GLP-1 receptor agonists
• cardiovascular health
• metabolic disease
• long-term strategy
• sustainable lifestyle
• weight loss

Keywords

• GLP-1
• cardiovascular risk
• semaglutide
• metabolic health
• long-term use
• weight loss
• lifestyle strategies

Mentioned in this episode

Organizations: healthcare provider

Products: GLP-1 receptor agonists, semaglutide

More episodes of Metabolic Mind

• BITESIZE: The New Protein Guidelines Reignited the Plant vs. Animal Debate · June 12, 2026 · 7 min
• BITESIZE: Omega-3 Supplements and Cognitive Decline? Here’s the Full Story · June 10, 2026 · 8 min
• Whole-Person Psychiatry Is Changing Mental Health Care—with Meru Health’s Kristian Ranta · June 8, 2026 · 31 min
• New Study from 25-Year Eating Disorder Expert · June 5, 2026 · 36 min
• First Keto Trial for Anorexia Nervosa: 72% Showed Recovery · June 3, 2026 · 4 min
• BITESIZE: New Study: Why Did This Drug Lower Cholesterol But Not Heart Plaque? · June 1, 2026 · 4 min